A live measles-vectored COVID-19 vaccine induces strong immunity and protection from SARS-CoV-2 challenge in mice and hamsters.
Adenoviridae
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ administration & dosage
Cricetinae
Cytokines
Female
Genetic Vectors
Immunity
Immunization
Immunization, Secondary
Male
Measles Vaccine
/ immunology
Mesocricetus
Mice
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ genetics
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
01
01
2021
accepted:
05
10
2021
entrez:
2
11
2021
pubmed:
3
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Several COVID-19 vaccines have now been deployed to tackle the SARS-CoV-2 pandemic, most of them based on messenger RNA or adenovirus vectors.The duration of protection afforded by these vaccines is unknown, as well as their capacity to protect from emerging new variants. To provide sufficient coverage for the world population, additional strategies need to be tested. The live pediatric measles vaccine (MV) is an attractive approach, given its extensive safety and efficacy history, along with its established large-scale manufacturing capacity. We develop an MV-based SARS-CoV-2 vaccine expressing the prefusion-stabilized, membrane-anchored full-length S antigen, which proves to be efficient at eliciting strong Th1-dominant T-cell responses and high neutralizing antibody titers. In both mouse and golden Syrian hamster models, these responses protect the animals from intranasal infectious challenge. Additionally, the elicited antibodies efficiently neutralize in vitro the three currently circulating variants of SARS-CoV-2.
Identifiants
pubmed: 34725327
doi: 10.1038/s41467-021-26506-2
pii: 10.1038/s41467-021-26506-2
pmc: PMC8560864
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Cytokines
0
Measles Vaccine
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6277Informations de copyright
© 2021. The Author(s).
Références
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Viral Immunol. 2010 Oct;23(5):509-19
pubmed: 20883165
BMJ. 2010 Nov 30;341:c6495
pubmed: 21118875
J Virol. 2015 Nov;89(22):11654-67
pubmed: 26355094
iScience. 2020 Jun 26;23(6):101212
pubmed: 32512386
Virology. 2014 Mar;452-453:32-41
pubmed: 24606680
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Virology. 2009 May 25;388(1):191-203
pubmed: 19345390
Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):
pubmed: 33688034
Lancet Infect Dis. 2015 May;15(5):519-27
pubmed: 25739878
Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60
pubmed: 15150417
J Virol. 2006 Jan;80(2):941-50
pubmed: 16378996
J Virol. 2003 Nov;77(21):11546-54
pubmed: 14557640
Curr Gene Ther. 2011 Aug;11(4):307-20
pubmed: 21453277
J Vis Exp. 2014 Nov 04;(93):e52065
pubmed: 25407402
Virol Sin. 2018 Apr;33(2):201-204
pubmed: 29541941
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Microbes Infect. 2018 Oct - Nov;20(9-10):493-500
pubmed: 29410084
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
J Virol. 2017 Sep 27;91(20):
pubmed: 28768856
J Virol. 2004 Jul;78(13):6938-45
pubmed: 15194770
Vaccine. 2013 Aug 12;31(36):3718-25
pubmed: 23742993
J Virol. 2007 Oct;81(19):10597-605
pubmed: 17634218
Sci Transl Med. 2019 Oct 2;11(512):
pubmed: 31578242
Virology. 2018 Nov;524:151-159
pubmed: 30199752
Vaccine. 2002 Jan 15;20(7-8):1134-40
pubmed: 11803074
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Infect Dis. 2019 Dec;19(12):1363-1370
pubmed: 31543249
Genome Res. 2017 May;27(5):824-834
pubmed: 28298430
Lancet. 2019 Dec 22;392(10165):2718-2727
pubmed: 30409443
J Virol. 2005 Jun;79(11):6900-8
pubmed: 15890929
N Engl J Med. 2007 Nov 8;357(19):1903-15
pubmed: 17989383
J Immunol. 2004 Sep 15;173(6):4050-7
pubmed: 15356154
Virology. 2018 Jun 11;521:99-107
pubmed: 29902727
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Vaccine. 2021 Jan 22;39(4):667-677
pubmed: 33342635
Vaccine. 2006 Feb 13;24(7):1028-34
pubmed: 16388880
Vaccine. 2007 Apr 20;25(16):2974-83
pubmed: 17303293
Nature. 2020 Jan;577(7792):605-607
pubmed: 31992880
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Annu Rev Immunol. 1990;8:303-33
pubmed: 1693082
J Virol. 1993 Aug;67(8):4822-30
pubmed: 8392616
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
J Virol. 2019 Jan 17;93(3):
pubmed: 30429338
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
EBioMedicine. 2016 Aug;10:312-7
pubmed: 27498365
Sci Rep. 2018 Oct 24;8(1):15701
pubmed: 30356097
Sci Transl Med. 2021 Jun 2;13(596):
pubmed: 33941622
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32657-32666
pubmed: 33257540
Virol Sin. 2020 Jun;35(3):337-339
pubmed: 32198713
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508